Growth Suppression and Therapy Sensitization of Breast Cancer.
Abstract
The purpose of this project is to provide a rationale and pre-clinical evaluation of p53- based approaches to growth suppression and therapy sensitization of breast cancer. The scope of the first year's study was to evaluate drugs that could be used in combination with p53 to achieve enhanced tumor suppression and to develop in vitro DNA repair assays that would enable us to study how p53-mediated suppression was affected by DNA repair. We have observed that p53 sensitizes breast cancer cells to DNA damaging chemotherapeutic drugs such as cisplatin, and to agents that inhibit DNA repair, but not to TaxotereTM, a mitotic inhibitor, or 5-fluorouracil, an antimetabolite. Using DNA repair assays we have observed a correlation between down regulation of DNA repair, and increased sensitivity to p53. These results suggest a new biological strategy for breast cancer treatment employing pS3 in combination with DNA repair inhibitors or with DNA damaging agents.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 1997
- Accession Number
- ADB229447
Entities
People
- Ruth A. Gjerset